摘要
目的:研究疏风醒鼻法对变应性鼻炎(AR)大鼠Th1/Th2免疫平衡的影响。方法:24只SD大鼠随机分为正常组、模型组、中药组。观察大鼠体质量变化情况,评估AR行为学评分,HE观察鼻黏膜病理改变,免疫组化检测鼻黏膜白细胞介素-4(IL-4)、信号转导及转录激活因子(STAT)5、STAT6、GATA3表达,ELISA测定血清IgE、IL-4水平,RT-PCR检测鼻黏膜组织中STAT5、STAT6、GATA3 mRNA表达,Western Blot检测鼻黏膜组织中IL-4、STAT5、STAT6、GATA3蛋白表达。结果:与模型组比较,治疗后中药组大鼠体质量显著改善(P<0.05),AR行为学评分降低(P<0.01),鼻黏膜病理改变减轻,鼻黏膜组织中IL-4、STAT5、STAT6、GATA3表达均下降(P<0.05,P<0.01),血清IgE、IL-4水平均降低(P<0.01),鼻黏膜组织STAT5、STAT6、GATA3 mRNA和蛋白表达水平均显著下降(P<0.05)。结论:疏风醒鼻法能够显著改善AR大鼠鼻黏膜炎性症状,其作用机制可能和调节Th1/Th2免疫平衡及相关细胞因子关系密切。
Objective:To study the effects of Shufeng Xingbi therapy on Th1/Th2 immune balance in allergic rhinitis(AR)rats.Methods:Twenty-four SD rats were randomly divided into normal control group,model group and Chinese herbal medicine group.The body weight of the rats was observed and the AR behavioral score was assessed.The pathological change of nasal mucosa was observed by HE.The expressions of IL-4,STAT5,STAT6 and GATA3 in nasal mucosa were detected by immunohistochemistry,and the levels of serum IgE and IL-4 were determined by ELISA.The mRNA expressions of STAT5,STAT6 and GATA3 in nasal mucosa tissue were detected by RT-PCR,and protein expressions of IL-4,STAT5,STAT6 and GATA3 in nasal mucosa tissue were detected by Western Blot.Results:Compared with the model group,the body weight of the treated rats was significantly improved(P<0.05),the AR behavioral score was significantly reduced(P<0.01),and the pathological changes of nasal mucosa were alleviated.The expression levels of IL-4,STAT5,STAT6 and GATA3 in the nasal mucosa were all significantly decreased(P<0.05,P<0.01).Serum IgE and IL-4 levels were significantly decreased(P<0.01),and the mRNA and protein expression levels of STAT5,STAT6 and GATA3 in nasal mucosa were significantly decreased(P<0.05).Conclusion:Shufeng Xingbi therapy can significantly improve the inflammatory symptoms of nasal mucosa in AR rats,and its mechanism may be closely related to the regulation of Th1/Th2 immune balance and related cytokines.
作者
颜水平
庄翔莉
邱彩霞
艾斯
黄丽珍
郑健
YAN Shui-ping;ZHUANG Xiang-li;QIU Cai-xia;AI Si;HUANG Li-zhen;ZHENG Jian(Academy of Integrative Medicine,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China;AffiliatedPeople’s Hospital of Fujian University of Traditional Chinese Medicine,Fuzhou 350004,China;Affiliated RehabilitationHospital of Fujian University of Traditional Chinese Medicine,Fuzhou 350001,China;Shenzhen Hospital ofGuangzhou University of Chinese Medicine,Shenzhen 510006,China;Institute of Pediatrics of TraditionalChinese Medicine,Fujian University of Traditional Chinese Medicine,Fuzhou 350004,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2023年第5期2298-2303,共6页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
福建中医药大学附属人民医院国家临床研究基地(No.JDZX201913)
福建省自然科学基金面上项目(No.2021J01900)。
